Table 2.
Anatomical sitea | No. of isolatesb | % Susceptible (no. susceptible/no. available for testing)b | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTX | CAZ | FEP | P/T | CPM | GNT | TOB | AMK | FQ | TMP-SMX | TET | NIT | ||
All | 44 | 0 | 0 | 0 | 100 (31/31) | 100 | 82 | 82 | 100 (40/40) | 52 (22/42) | 38 (16/42) | 22 (6/27) | 97 (30/31) |
Urine | 31 | 0 | 0 | 0 | 100 (21/21) | 100 | 90 | 90 | 100 (28/28) | 52 (15/29) | 33 (10/30) | 24 (6/25) | 97 (30/31) |
Respiratory | 7 | 0 | 0 | 0 | 100 (4/4) | 100 | 71 | 71 | 100 | 71 | 83 (5/6) | 0 (0/1) | ND |
Blood | 4 | 0 | 0 | 0 | 100 | 100 | 50 | 50 | 100 (3/3) | 50 | 25 | 0 (0/1) | ND |
Other | 2 | 0 | 0 | 0 | 100 | 100 | 50 | 50 | 100 | 0 | 0 | ND | ND |
CTX ceftriaxone, CAZ cefazolin, FEP cefepime, P/T piperacillin-tazobactam, CPM carbapenem (includes meropenem ertapenem or imipenem), GNT gentamicin, TOB tobramycin, AMK amikacin, FQ fluoroquinolones (includes ciprofloxacin and levofloxacin), TMP-SMX trimethoprim-sulfamethoxazole, TET tetracycline, NIT nitrofurantoin, ATN aztreonam, ND no data
aRespiratory includes bronchoalveolar lavage fluid, trachea, and sputum cultures. “Other” includes abscesses
bSusceptibility data not available for all antibiotics for all isolates